Amgen (NASDAQ: AMGN) Q2 2026 Earnings Tuesday August 4 Beat Consensus and Raised Full-Year 2026 Revenue Guidance to $38.2-39.4 Billion (Midpoint $38.8 Billion Above the $37.7 Billion Consensus) With Adjusted EPS Guidance $22.30-23.50 (Midpoint $22.90 Above the $22.35 Consensus); Growth Drivers Include Repatha (Evolocumab PCSK9 Antibody) at $953 Million (+37% YoY), EVENITY at $714 Million (+38%), TEZSPIRE at $486 Million (+42%), and UPLIZNA at $335 Million (+90%); MariTide Phase 3 Obesity Program Continues Advancing With Multiple Trials Across Weight Management, Cardiovascular Outcomes, and Heart Failure Indications Though Cantor Fitzgerald Flagged a 4% Bone Mineral Density Decline From Phase 1 Data as a Potential Safety Concern
Amgen (NASDAQ: AMGN) reported Q2 2026 earnings Tuesday August 4, 2026 with a beat and raised full-year 2026 revenue guidance to $38.2-39.4 billion (midpoint $38.8 billion above the $37.7 billion analyst consensus). Adjusted EPS guidance is $22.30-23.50 (midpoint $22.90 above the $22.35 consensus). Growth-portfolio product performance drove the beat: Repatha (evolocumab, PCSK9 monoclonal antibody) reached $953 million (+37% year-over-year); EVENITY (romosozumab for osteoporosis) $714 million (+38%); TEZSPIRE (tezepelumab for severe asthma) $486 million (+42%); UPLIZNA (inebilizumab for neuromyelitis optica spectrum disorder) $335 million (+90%). The MariTide (maridebart cafraglutide, monthly-injectable antibody-peptide conjugate targeting GLP-1 and GIPR) Phase 3 obesity program continues advancing with multiple trials across weight management, cardiovascular outcomes, and heart failure indications; earnings-call commentary described 2026 as a year of disciplined MariTide data generation. Analyst scrutiny remains on the 4% bone mineral density decline observed in Phase 1 MariTide data (per Cantor Fitzgerald analysis) as a potential regulatory hurdle and safety disadvantage versus GLP-1 receptor agonist competitors. Amgen shares closed up 3.03% on August 4.